Laura Belvisi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4116142/publications.pdf

Version: 2024-02-01

		159573	254170
104	2,614	30	43
papers	citations	h-index	g-index
113	113	113	2592
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Conformational Preferences of Peptides Containing Reverse-Turn Mimetic Bicyclic Lactams: Inverse \hat{I}^3 -Turns versus Type-llâ \in 2 \hat{I}^2 -Turns â \in 4 Insights into \hat{I}^2 -Hairpin Stability., 1999, 1999, 389-400.		92
2	Biological and molecular properties of a new $\hat{l}\pm v\hat{l}^23/\hat{l}\pm v\hat{l}^25$ integrin antagonist. Molecular Cancer Therapeutics, 2005, 4, 1670-1680.	4.1	75
3	Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: ligand presentation using molecular rods. Chemical Communications, 2015, 51, 3816-3819.	4.1	74
4	Synthesis and Biological Evaluation (in Vitro and in Vivo) of Cyclic Arginine–Glycine–Aspartate (RGD) Peptidomimetic–Paclitaxel Conjugates Targeting Integrin α _V β ₃ . Journal of Medicinal Chemistry, 2012, 55, 10460-10474.	6.4	68
5	Innovative Linker Strategies for Tumorâ€Targeted Drug Conjugates. Chemistry - A European Journal, 2019, 25, 14740-14757.	3.3	68
6	Cyclic RGD Peptidomimetics Containing Bifunctional Diketopiperazine Scaffolds as New Potent Integrin Ligands. Chemistry - A European Journal, 2012, 18, 6195-6207.	3.3	62
7	Targeting integrins: Insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. Bioorganic and Medicinal Chemistry, 2006, 14, 169-180.	3.0	61
8	Second generation of fucose-based DC-SIGN ligands: affinity improvement and specificity versus Langerin. Organic and Biomolecular Chemistry, 2011, 9, 5778.	2.8	60
9	N-3-Substituted Pyrimidinones as Potent, Orally Active, AT1 Selective Angiotensin II Receptor Antagonists. Journal of Medicinal Chemistry, 1995, 38, 4806-4820.	6.4	59
10	Cyclic RGDâ€Peptidomimetics Containing Bifunctional Diketopiperazine Scaffolds as New Potent Integrin Ligands. Chemistry - A European Journal, 2009, 15, 12184-12188.	3.3	58
11	Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides. Organic Letters, 2001, 3, 1001-4.	4.6	56
12	Synthesis of Gd and ⁶⁸ Ga Complexes in Conjugation with a Conformationally Optimized RGD Sequence as Potential MRI and PET Tumorâ€lmaging Probes. ChemMedChem, 2012, 7, 1084-1093.	3.2	53
13	Potent Integrin Antagonists from a Small Library of RGD-Including Cyclic Pseudopeptides. Organic Letters, 2001, 3, 1001-1004.	4.6	49
14	Grafting Aminocyclopentane Carboxylic Acids onto the RGD Tripeptide Sequence Generates Low Nanomolar αVÎ ² 3/αVÎ ² 5Integrin Dual Binders. Journal of Medicinal Chemistry, 2005, 48, 7675-7687.	6.4	49
15	Synthesis and Biological Evaluation of RGD Peptidomimetic–Paclitaxel Conjugates Bearing Lysosomally Cleavable Linkers. Chemistry - A European Journal, 2015, 21, 6921-6929.	3.3	48
16	Synthesis and Conformational Studies of Peptidomimetics Containing a New Bifunctional Diketopiperazine Scaffold Acting as a β-Hairpin Inducer. Journal of Organic Chemistry, 2008, 73, 652-660.	3.2	47
17	Conformationally constrained dipeptides: Synthesis of 7,5- and 6,5-fused bicyclic lactams by stereoselective radical cyclizations. Tetrahedron Letters, 1995, 36, 625-628.	1.4	46
18	Structural investigations of isomeric oxidised forms of hyperforin by HPLC-NMR and HPLC-MSn. Phytochemical Analysis, 2003, 14, 290-297.	2.4	45

#	Article	IF	CITATIONS
19	Cyclic RGDâ€Containing Functionalized Azabicycloalkane Peptides as Potent Integrin Antagonists for Tumor Targeting. ChemMedChem, 2009, 4, 615-632.	3.2	44
20	?v?3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology. Current Topics in Medicinal Chemistry, 2015, 16, 314-329.	2.1	44
21	Conformational Analysis of Azabicycloalkane Amino Acid Scaffolds as Reverse-Turn Inducer Dipeptide Mimics. European Journal of Organic Chemistry, 2000, 2000, 2563-2569.	2.4	43
22	New \hat{I}^2 -Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins. Journal of Medicinal Chemistry, 2016, 59, 9721-9742.	6.4	43
23	Design, Synthesis, and Biological Evaluation of Novel cRGD–Paclitaxel Conjugates for Integrin-Assisted Drug Delivery. Bioconjugate Chemistry, 2012, 23, 1610-1622.	3.6	41
24	Practical stereoselective synthesis of conformationally constrained unnatural proline-based amino acids and peptidomimetics. Tetrahedron, 2001, 57, 6463-6473.	1.9	39
25	Functionalized Azabicycloalkane Amino Acids by Nitrone 1,3-Dipolar Intramolecular Cycloaddition. Journal of Organic Chemistry, 2005, 70, 4124-4132.	3.2	39
26	A new optical imaging probe targeting $\langle i \rangle \hat{l} \pm \langle i \rangle \langle sub \rangle V \langle sub \rangle \langle i \rangle \hat{l}^2 \langle i \rangle \langle sub \rangle 3 \langle sub \rangle$ integrin in glioblastoma xenografts. Contrast Media and Molecular Imaging, 2011, 6, 449-458.	0.8	39
27	STD and trNOESY NMR Study of Receptor–Ligand Interactions in Living Cancer Cells. ChemBioChem, 2011, 12, 695-699.	2.6	39
28	Rational design, synthesis and characterization of potent, non-peptidic Smac mimics/XIAP inhibitors as proapoptotic agents for cancer therapy. Bioorganic and Medicinal Chemistry, 2009, 17, 5834-5856.	3.0	36
29	Fast Cyclization of a Prolineâ€Derived Selfâ€Immolative Spacer Improves the Efficacy of Carbamate Prodrugs. Angewandte Chemie - International Edition, 2020, 59, 4176-4181.	13.8	35
30	The first asymmetric synthesis of enantiopure .alphasulfenyl dithioacetals and .alphasulfenyl aldehydes. Journal of Organic Chemistry, 1993, 58, 3165-3168.	3.2	33
31	A 3D QSAR CoMFA study of non-peptide angiotensin II receptor antagonists. Journal of Computer-Aided Molecular Design, 1996, 10, 567-582.	2.9	33
32	Cyclic <i>iso</i> DGR and RGD Peptidomimetics Containing Bifunctional Diketopiperazine Scaffolds are Integrin Antagonists. Chemistry - A European Journal, 2015, 21, 6265-6271.	3.3	33
33	Stereoselective radical-mediated cyclization of norephdrine derived $\hat{l}\pm$ -iodoamides: synthesis of enantiopure pyrrolidines and trandition state modelling 1. Tetrahedron, 1992, 48, 3945-3960.	1.9	32
34	Antiangiogenic Effect of Dual/Selective $\hat{l}\pm <$ sub>5 $\hat{l}^2 <$ sub>1 $\hat{l}^1 <$ sub>v $\hat{l}^2 <$ sub>3 Integrin Antagonists Designed on Partially Modified Retro-Inverso Cyclotetrapeptide Mimetics. Journal of Medicinal Chemistry, 2010, 53, 106-118.	6.4	29
35	Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization. Bioorganic and Medicinal Chemistry, 2012, 20, 6709-6723.	3.0	29
36	Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrinâ€√argeted Conjugate. Chemistry - A European Journal, 2019, 25, 1696-1700.	3.3	29

#	Article	IF	CITATIONS
37	Cyclic <i>iso</i> DGR Peptidomimetics as Lowâ€Nanomolar α _v β ₃ Integrin Ligands. Chemistry - A European Journal, 2013, 19, 3563-3567.	3.3	28
38	Synthesis of Azabicycloalkane Amino Acid Scaffolds as Reverse-Turn Inducer Dipeptide Mimics. European Journal of Organic Chemistry, 2000, 2000, 2571-2581.	2.4	27
39	A Potent Integrin Antagonist from a Small Library of Cyclic RGD Pentapeptide Mimics Including Benzylâ€ S ubstituted Azabicycloalkane Amino Acids. ChemMedChem, 2008, 3, 1589-1603.	3.2	27
40	Multivalency Increases the Binding Strength of RGD Peptidomimeticâ€Paclitaxel Conjugates to Integrin α _V β ₃ . Chemistry - A European Journal, 2017, 23, 14410-14415.	3.3	27
41	Stem-like Cancer Cells in a Dynamic 3D Culture System: A Model to Study Metastatic Cell Adhesion and Anti-cancer Drugs. Cells, 2019, 8, 1434.	4.1	27
42	Synthesis and Biological Evaluation of RGD and <i>i>iso</i> DGRâ€"Monomethyl Auristatin Conjugates Targeting Integrin α _V β ₃ . ChemMedChem, 2019, 14, 938-942.	3.2	26
43	Stereoselective radical-mediated cyclization of norephedrine derived o-bromobenzamides: Enantioselective synthesis of 4-substituted 1,2,3,4-tetrahydroisoquinolines. Tetrahedron: Asymmetry, 1993, 4, 273-280.	1.8	25
44	Synthesis, Characterization, and Biological Evaluation of a Dualâ€Action Ligand Targeting α _v β ₃ Integrin and VEGF Receptors. ChemistryOpen, 2015, 4, 633-641.	1.9	25
45	Transferred-NOE NMR experiments on intact human platelets: receptor-bound conformation of RGD-peptide mimics. Organic and Biomolecular Chemistry, 2008, 6, 258-262.	2.8	24
46	Synthesis of substituted conformationally constrained 6,5- and 7,5-fused bicyclic lactams as dipeptide mimics. Tetrahedron, 2003, 59, 6241-6250.	1.9	22
47	Development of Isoxazolineâ€Containing Peptidomimetics as Dual α _v β ₃ and α ₅ β ₁ Integrin Ligands. ChemMedChem, 2011, 6, 2264-2272.	3.2	22
48	Determination of the binding epitope of RGD-peptidomimetics to $\hat{l} \pm v \hat{l}^2 3$ and $\hat{l} \pm IIlb \hat{l}^2 3$ integrin-rich intact cells by NMR and computational studies. Organic and Biomolecular Chemistry, 2013, 11, 3886.	2.8	22
49	Insights into the Binding of Cyclic RGD Peptidomimetics to α ₅ β ₁ Integrin by using Live-Cell NMR And Computational Studies. ChemistryOpen, 2017, 6, 128-136.	1.9	21
50	Assessing the influence of electrostatic schemes on molecular dynamics simulations of secondary structure forming peptides. Journal of Physics Condensed Matter, 2006, 18, S329-S345.	1.8	20
51	Homo- and heterodimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part I: Synthesis. Bioorganic and Medicinal Chemistry, 2012, 20, 6687-6708.	3.0	20
52	Metadynamics Simulations Rationalise the Conformational Effects Induced by ⟨i⟩N⟨/i⟩â€Methylation of RGD Cyclic Hexapeptides. Chemistry - A European Journal, 2015, 21, 14165-14170.	3.3	20
53	Nonpeptide Angiotensin II Receptor Antagonists. Synthesis, in vitro Activity, and Molecular Modeling Studies of N-[(Heterobiaryl)methyl]imidazoles. Journal of Medicinal Chemistry, 1994, 37, 3928-3938.	6.4	19
54	Modulation of $\hat{l}\pm v\hat{l}^23$ - and $\hat{l}\pm 5\hat{l}^21$ -integrin-mediated adhesion by dehydro- \hat{l}^2 -amino acids containing peptidomimetics. European Journal of Medicinal Chemistry, 2013, 66, 258-268.	5.5	19

#	Article	IF	Citations
55	Cyclic RGD Peptides Containing Azabicycloalkane Reverse-Turn Mimics. Helvetica Chimica Acta, 2002, 85, 4353-4368.	1.6	18
56	Synthesis and conformational analysis of an α-d-mannopyranosyl-(1â†'6)-α-d-mannopyranose mimic. Carbohydrate Research, 20 342, 1859-1868.	00 27. 3	18
57	First round of a focused library of cholera toxin inhibitors. Carbohydrate Research, 2007, 342, 1651-1660.	2.3	18
58	Investigating the Interaction of Cyclic RGD Peptidomimetics with $\hat{l}\pm V\hat{l}^26$ Integrin by Biochemical and Molecular Docking Studies. Cancers, 2017, 9, 128.	3.7	18
59	A conformational study of N-tosyl oxazolidines using molecular mechanics and crystallography. Journal of Molecular Structure, 1994, 318, 189-202.	3.6	17
60	Antitumor Activity of a Novel Homodimeric SMAC Mimetic in Ovarian Carcinoma. Molecular Pharmaceutics, 2014, 11, 283-293.	4.6	17
61	Crystal Structure of Human E-Cadherin-EC1EC2 in Complex with a Peptidomimetic Competitive Inhibitor of Cadherin Homophilic Interaction. Journal of Medicinal Chemistry, 2016, 59, 5089-5094.	6.4	17
62	Tumor Targeting with an <i>iso</i> DGR–Drug Conjugate. Chemistry - A European Journal, 2017, 23, 7910-7914.	3. 3	17
63	Rationally Designed Bicyclic Lactams Control Different Turn Motifs and Folding Patterns in Hexapeptide Mimics., 2000, 2000, 695-699.		16
64	Computational design of novel peptidomimetic inhibitors of cadherin homophilic interactions. Organic and Biomolecular Chemistry, 2015, 13, 2570-2573.	2.8	16
65	A 3D QSAR approach to the search for geometrical similarity in a series of nonpeptide angiotensin II receptor antagonists. Journal of Computer-Aided Molecular Design, 1994, 8, 211-220.	2.9	15
66	Design and synthesis of conformationally constrained arginal thrombin inhibitors. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 2205-2210.	2.2	15
67	Foldamers of bifunctional diketopiperazines displaying a \hat{I}^2 -bend ribbon structure. Tetrahedron Letters, 2010, 51, 4278-4280.	1.4	15
68	Thermodynamically–Weighted Conformational Ensemble of Cyclic RGD Peptidomimetics from NOE Data. Journal of Physical Chemistry B, 2016, 120, 7098-7107.	2.6	15
69	Stereoselective synthesis of 6,5-bicyclic reverse-turn peptidomimetics. Tetrahedron, 1998, 54, 5325-5336.	1.9	14
70	Targeting Integrin \hat{l} + $\langle sub \rangle V \langle sub \rangle \hat{l}^2 \langle sub \rangle 3 \langle sub \rangle$ with Theranostic RGD-Camptothecin Conjugates Bearing a Disulfide Linker: Biological Evaluation Reveals a Complex Scenario. ChemistrySelect, 2017, 2, 4759-4766.	1.5	14
71	\hat{l}^2 -Glucuronidase triggers extracellular MMAE release from an integrin-targeted conjugate. Organic and Biomolecular Chemistry, 2019, 17, 4705-4710.	2.8	14
72	Synthesis of Easyâ€toâ€Functionalize AzaÂbicycloalkane Scaffolds as Dipeptide Turn Mimics en Route to cRGDâ€Based Bioconjugates. European Journal of Organic Chemistry, 2015, 2015, 7557-7570.	2.4	12

#	Article	IF	CITATIONS
73	High Affinity vs. Native Fibronectin in the Modulation of $\hat{l}\pm v\hat{l}^23$ Integrin Conformational Dynamics: Insights from Computational Analyses and Implications for Molecular Design. PLoS Computational Biology, 2017, 13, e1005334.	3.2	12
74	Nonpeptide Integrin Antagonists: RGD Mimetics Incorporating Substituted Azabicycloalkanes as Amino Acid Replacements. European Journal of Organic Chemistry, 2007, 2007, 1309-1317.	2.4	10
75	Bromineâ€Promoted Glycosidation of Conformationally Superarmed Thioglycosides. Chemistry - A European Journal, 2019, 25, 11831-11836.	3.3	10
76	Rational Design of Antiangiogenic Helical Oligopeptides Targeting the Vascular Endothelial Growth Factor Receptors. Frontiers in Chemistry, 2019, 7, 170.	3.6	10
77	The Importance of Detail: How Differences in Ligand Structures Determine Distinct Functional Responses in Integrin \hat{l}_{\pm} v \hat{l}^2 3. Chemistry - A European Journal, 2019, 25, 5959-5970.	3.3	10
78	Simulation of carbohydrate-protein interactions: computer-aided design of a second generation GM1 mimic. Journal of Computer-Aided Molecular Design, 2001, 15, 117-128.	2.9	9
79	A critical assessment of force field accuracy against NMR data for cyclic peptides containing \hat{l}^2 -amino acids. Physical Chemistry Chemical Physics, 2018, 20, 15807-15816.	2.8	9
80	Structure-activity relationship of Ca2+ channel blockers: A study using conformational analysis and chemometric methods. Journal of Computer-Aided Molecular Design, 1991, 5, 571-584.	2.9	8
81	A NMR and computational study of Smac mimics targeting both the BIR2 and BIR3 domains in XIAP protein. Organic and Biomolecular Chemistry, 2012, 10, 3278.	2.8	8
82	Fast Cyclization of a Prolineâ€Derived Selfâ€Immolative Spacer Improves the Efficacy of Carbamate Prodrugs. Angewandte Chemie, 2020, 132, 4205-4210.	2.0	8
83	Stereoselective synthesis of Cα-tetrasubstituted azabicyclo[X.3.0]alkane amino acids. Tetrahedron Letters, 2004, 45, 6311-6315.	1.4	7
84	New Insights into the Molecular Mechanism of E-Cadherin-Mediated Cell Adhesion by Free Energy Calculations. Journal of Chemical Theory and Computation, 2015, 11, 1354-1359.	5.3	7
85	A trifunctional self-immolative spacer enables drug release with two non-sequential enzymatic cleavages. Chemical Communications, 2021, 57, 7778-7781.	4.1	7
86	On the role of the molecular electrostatic potential in modelling the activity of non-peptide angiotensin II receptor antagonists. Computational and Theoretical Chemistry, 1993, 281, 237-252.	1.5	6
87	Prediction and Validation of a Druggable Site on Virulence Factor of Drug Resistant <i>Burkholderia cenocepacia</i> **. Chemistry - A European Journal, 2021, 27, 10341-10348.	3.3	6
88	Synthesis of Functionalized Azabicycloalkane Amino Acids as Dipeptide Mimics. Synthesis, 2006, 2006, 1133-1140.	2.3	5
89	Complete Characterization of Extracts of <i>Onopordum illyricum</i> L. (Asteraceae) by HPLC/PDA/ESIMS and NMR. Natural Product Communications, 2008, 3, 1934578X0800301.	0.5	5
90	Exploring E-cadherin-peptidomimetics interaction using NMR and computational studies. PLoS Computational Biology, 2019, 15, e1007041.	3.2	5

#	Article	IF	CITATIONS
91	Cyclic RGD and isoDGR Integrin Ligands Containing cis-2-amino-1-cyclopentanecarboxylic (cis-Î ² -ACPC) Scaffolds. Molecules, 2020, 25, 5966.	3.8	5
92	Advanced Pyrrolidineâ€Carbamate Selfâ€Immolative Spacer with Tertiary Amine Handle Induces Superfast Cyclative Drug Release. ChemMedChem, 2022, 17, .	3.2	5
93	Design and synthesis of nonpeptide angiotensin II receptor antagonists featuring acyclic imidazole-mimicking structural units. Bioorganic and Medicinal Chemistry, 1998, 6, 2013-2027.	3.0	4
94	Design, Synthesis, Conformational Analysis and Application of AzabicycloÂalkane Amino Acids as Constrained Dipeptide Mimics. Synlett, 2004, 2004, 1449-1471.	1.8	4
95	New potent \hat{l}_{\pm} (sub>v \hat{l}^{2} (sub> 3 integrin ligands based on azabicycloalkane (\hat{l}^{3} , \hat{l}_{\pm})-dipeptide mimics. Organic and Biomolecular Chemistry, 2016, 14, 3221-3233.	2.8	4
96	A dimeric bicyclic RGD ligand displays enhanced integrin binding affinity and strong biological effects on U-373 MG glioblastoma cells. Organic and Biomolecular Chemistry, 2019, 17, 8913-8917.	2.8	4
97	Side chain effect in the modulation of $\hat{l}\pm v\hat{l}^23/\hat{l}\pm 5\hat{l}^21$ integrin activity via clickable isoxazoline-RGD-mimetics: development of molecular delivery systems. Scientific Reports, 2020, 10, 7410.	3.3	4
98	Title is missing!. Organic Letters, 2001, 3, 1001-1004.	4.6	2
99	Non peptide angiotensin II receptor antagonists: A 3D-QSAR comfa-like approach. AIP Conference Proceedings, 1995, , .	0.4	1
100	Functionalized 2â∈Hydroxybenzaldehydeâ∈PEG Modules as Portable Tags for the Engagement of Protein Lysine ϵâ€Amino Groups. European Journal of Organic Chemistry, 2021, 2021, 1763-1767.	2.4	1
101	Modulation of $\hat{l}\pm v\hat{l}^2$ 3- and $\hat{l}\pm 5\hat{l}^2$ 1-integrin-mediated adhesion by dehydro- \hat{l}^2 -amino acids containing peptidomimetics., 2013, 66, 258-258.		1
102	Inside Cover: Cyclic RGD Peptidomimetics Containing Bifunctional Diketopiperazine Scaffolds as New Potent Integrin Ligands (Chem. Eur. J. 20/2012). Chemistry - A European Journal, 2012, 18, 6106-6106.	3.3	0
103	Frontispiece: Multivalency Increases the Binding Strength of RGD Peptidomimeticâ€Paclitaxel Conjugates to Integrin α _V β ₃ . Chemistry - A European Journal, 2017, 23, .	3.3	0
104	Frontispiece: Innovative Linker Strategies for Tumorâ€Targeted Drug Conjugates. Chemistry - A European Journal, 2019, 25, .	3.3	0